Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine

Table 1 Distribution of NAT polymorphisms in AS patients and healthy controls

Alleles/Genotypes/Acetylator genotypes		AS		HC		χ²	P
Alleles/Genotypes/Acetylator genotypes		N	%	N	%	χ²	P
NAT1 Alleles	NAT14*	268	50.4	261	46.6	1.55	0.21
	NAT13*	101	19.0	108	19.3	0.02	0.90
	NAT110*	159	29.9	188	33.6	1.71	0.19
	NAT111*	4	0.7	3	0.5	-	0.72*
	Total	532		560
NAT1 Genotypes	NAT14/NAT14	75	28.2	65	23.2	1.78	0.18
	NAT14/NAT13	39	14.7	48	17.1	0.63	0.43
	NAT14/NAT110	77	28.9	80	28.6	0.01	0.92
	NAT14/NAT111	2	0.8	3	1.1	-	1.00*
	NAT13/NAT13	14	5.2	14	5.0	0.02	0.89
	NAT13/NAT110	34	12.8	32	11.4	0.24	0.63
	NAT13/ NAT111	0	0	0	0	-	-
	NAT110/NAT110	23	8.6	38	13.6	3.33	0.07
	NAT110/NAT111	2	0.8	0	0	-	-
	NAT111/NAT111	0	0	0	0	-	-
	Total	266		280
NAT1 Acetylator Genotypes	Fast	136	51.1	150	53.6	0.33	0.57
NAT1 Acetylator Genotypes	Slow	130	48.9	130	46.4	0.33	0.57
	Total	266		280
NAT2 Alleles	NAT24*	310	58.3	340	60.7	0.68	0.41
	NAT25*	18	3.4	18	3.2	0.02	0.88
	NAT26*	134	25.2	129	23.0	0.69	0.41
	NAT27*	70	13.1	73	13.1	0.00	0.95
	Total	532		560
NAT2 Genotypes	NAT24/NAT24	98	36.8	110	39.3	0.35	0.56
	NAT24/NAT25	9	3.4	10	3.6	0.01	0.91
	NAT24/NAT26	70	26.3	71	25.4	0.07	0.80
	NAT24/NAT27	35	13.2	39	13.9	0.07	0.79
	NAT25/NAT25	0	0	1	0.4	-	-
	NAT25/NAT26	6	2.3	2	0.7	-	0.17*
	NAT25/NAT27	3	1.1	4	1.4	-	1.00*
	NAT26/NAT26	18	6.8	18	6.4	0.03	0.87
	NAT26/NAT27	22	8.2	20	7.1	0.24	0.62
	NAT27/NAT27	5	1.9	5	1.8	-	1.00*
	Total	266		280
NAT2 Acetylator Genotypes	Fast	212	79.7	230	82.1	0.53	0.47
NAT2 Acetylator Genotypes	Slow	54	20.3	50	17.9	0.53	0.47
	Total	266		280
NAT2 fast acetylator genotype plus NAT110/NAT110		17	6.4	32	11.4	4.24	0.04

*Results of Fisher’s exact test; AS = Ankylosing Spondylitis; HC = healthy control; NAT1 = Arylamine N-acetyltransferases 1; NAT2 = Arylamine N-acetyltransferases 2; N = Number; χ² = Chi-squared test.

ISSN: 2050-6511